{"product_id":"tirzepatide-10mg-10-vials","title":"Tirzepatide – 10mg (10 Vials)","description":"\u003cstyle\u003e\n.plp-desc-rt{font-family:var(--font-body-family,Helvetica,Arial,sans-serif);color:rgba(18,18,18,.7)}\n.plp-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:400;line-height:1.7}\n.plp-desc-rt strong{color:#0e2a44;font-weight:600}\n.plp-desc-rt em{color:rgba(18,18,18,.5)}\n.plp-desc-rt sup{line-height:0}\n.plp-desc-rt sup a{font-size:11px;font-weight:600;color:#2279be;text-decoration:none;padding:0 1px}\n.plp-desc-rt sup a:hover{color:#0e2a44}\n\u003c\/style\u003e\n\u003cdiv class=\"plp-desc-rt\"\u003e\n\u003cp\u003e\u003cstrong\u003eTirzepatide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003edual GIP and GLP-1 receptor agonist\u003c\/strong\u003e — a single molecule that activates two incretin pathways at once. In peptide research this dual mechanism has drawn intense interest for its effects on appetite signaling, insulin response and \u003cstrong\u003ebody-weight regulation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eIn the landmark 72-week \u003cstrong\u003eSURMOUNT-1\u003c\/strong\u003e trial, participants on the 15 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 20.9%\u003c\/strong\u003e, versus 3.1% on placeb. \u003cstrong\u003e57%\u003c\/strong\u003e of that group lost a fifth or more of their body weight, and \u003cstrong\u003e91%\u003c\/strong\u003e lost at least 5%\u003csup\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eHead-to-head data reinforce the signal: in \u003cstrong\u003eSURPASS-2\u003c\/strong\u003e, tirzepatide produced greater weight loss than semaglutide — up to \u003cstrong\u003e5.5 kg more\u003c\/strong\u003e at the top dose — while lowering HbA1c by \u003cstrong\u003e2.30 points\u003c\/strong\u003e\u003csup\u003e\u003c\/sup\u003e. Its dual-receptor design is widely cited as why it outperforms single-pathway GLP-1 agonists.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the tirzepatide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Ziol ","offers":[{"title":"Default Title","offer_id":53712749789408,"sku":"T10-10","price":695.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0803\/9641\/9296\/files\/SUBSTITUA_A_LOGO_DA_PRIMELUB_POR_ESSA_QUE_EU_MANDEI_POR_FAVOR_6_73f16d5c-67f6-4f1f-ad79-7e9060c6b29f.png?v=1785282343","url":"https:\/\/ziol.shop\/products\/tirzepatide-10mg-10-vials","provider":"Ziol ","version":"1.0","type":"link"}